MA49772A - Agonistes benzo[b]thiophène de sting pour le traitement du cancer - Google Patents
Agonistes benzo[b]thiophène de sting pour le traitement du cancerInfo
- Publication number
- MA49772A MA49772A MA049772A MA49772A MA49772A MA 49772 A MA49772 A MA 49772A MA 049772 A MA049772 A MA 049772A MA 49772 A MA49772 A MA 49772A MA 49772 A MA49772 A MA 49772A
- Authority
- MA
- Morocco
- Prior art keywords
- sting
- agonists
- cancer treatment
- thiophene benzo
- thiophene
- Prior art date
Links
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 title 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 229930192474 thiophene Natural products 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762541174P | 2017-08-04 | 2017-08-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA49772A true MA49772A (fr) | 2021-04-21 |
Family
ID=65234123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA049772A MA49772A (fr) | 2017-08-04 | 2018-07-30 | Agonistes benzo[b]thiophène de sting pour le traitement du cancer |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11285131B2 (fr) |
| EP (1) | EP3661498A4 (fr) |
| JP (1) | JP2020530838A (fr) |
| AU (1) | AU2018311966A1 (fr) |
| CA (1) | CA3071538A1 (fr) |
| MA (1) | MA49772A (fr) |
| WO (1) | WO2019027858A1 (fr) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3523287T (pt) * | 2016-10-04 | 2021-10-06 | Merck Sharp & Dohme | Compostos de benzo[b]tiofeno como agonistas de sting |
| WO2019046511A1 (fr) | 2017-08-31 | 2019-03-07 | Sperovie Biosciences, Inc. | Composés, compositions et méthodes pour le traitement d'une maladie |
| GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
| JP7570235B2 (ja) | 2018-05-25 | 2024-10-21 | インサイト・コーポレイション | Ｓｔｉｎｇ活性化剤としての三環式複素環式化合物 |
| US11008344B2 (en) | 2018-07-31 | 2021-05-18 | Incyte Corporation | Tricyclic heteroaryl compounds as STING activators |
| WO2020028566A1 (fr) | 2018-07-31 | 2020-02-06 | Incyte Corporation | Composés amides hétéroaryles en tant qu'activateurs de sting |
| US11596692B1 (en) | 2018-11-21 | 2023-03-07 | Incyte Corporation | PD-L1/STING conjugates and methods of use |
| WO2020146237A1 (fr) | 2019-01-07 | 2020-07-16 | Incyte Corporation | Composés d'amide d'hétéroaryle en tant qu'activateurs de sting |
| BR112021018947A2 (pt) | 2019-03-28 | 2022-02-08 | Lupin Ltd | Compostos macrocíclicos como agonistas de sting |
| EP3964504A4 (fr) * | 2019-04-30 | 2022-12-28 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Composé de benzothiophène, son procédé de préparation et son utilisation |
| WO2020227159A2 (fr) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Métodes de modulation de l'activité immunitaire |
| WO2021007160A1 (fr) | 2019-07-05 | 2021-01-14 | Tambo, Inc. | Agents bioorthogonaux de trans-cyclooctène et leurs utilisations dans le traitement du cancer et l'immunothérapie |
| US11339159B2 (en) | 2019-07-17 | 2022-05-24 | Pfizer Inc. | Toll-like receptor agonists |
| GB201910304D0 (en) * | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| GB201910305D0 (en) * | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| CR20220029A (es) | 2019-07-22 | 2022-03-14 | Lupin Ltd | Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos |
| JP7843695B2 (ja) | 2019-08-02 | 2026-04-10 | メルサナ セラピューティクス インコーポレイテッド | がんの処置用のＳＴＩＮＧ（インターフェロン遺伝子刺激因子）アゴニストとしてのビス－［Ｎ－（（５－カルバモイル）－１Ｈ－ベンゾ［ｄ］イミダゾール－２－イル）－ピラゾール－５－カルボキサミド］誘導体および関連化合物 |
| EP4077318B1 (fr) | 2019-12-18 | 2025-10-15 | Ctxt Pty Ltd | Dimères de benzimidazole en tant que modulateurs de sting |
| IL296901A (en) | 2020-04-02 | 2022-12-01 | Mersana Therapeutics Inc | Antibody-drug conjugates comprising sting agonists |
| TW202200136A (zh) | 2020-04-10 | 2022-01-01 | 日商小野藥品工業股份有限公司 | 癌治療方法 |
| CN116056765A (zh) | 2020-08-07 | 2023-05-02 | 坦伯公司 | 反式环辛烯生物正交剂及在癌症和免疫疗法中的用途 |
| WO2023121939A1 (fr) * | 2021-12-23 | 2023-06-29 | Merck Sharp & Dohme Llc | Dérivés de benzothiophène substitués et leurs procédés d'utilisation |
| WO2024003773A1 (fr) | 2022-07-01 | 2024-01-04 | Pfizer Inc. | Composés de 2,7-naphtyridine en tant qu'inhibiteurs de mastl |
| AU2023302139A1 (en) | 2022-07-05 | 2024-12-19 | Pfizer Inc. | Pyrido[4,3-d]pyrimidine compounds |
| WO2024074977A1 (fr) | 2022-10-04 | 2024-04-11 | Pfizer Inc. | Composés 1h-pyrazolo-pyridine et -pyrimidine substitués |
| CN120379671A (zh) | 2022-10-18 | 2025-07-25 | 辉瑞公司 | 用于治疗癌症的化合物 |
| WO2024105563A1 (fr) | 2022-11-16 | 2024-05-23 | Pfizer Inc. | Dérivés de pyridone bicyclique substitués |
| CN116354922B (zh) * | 2023-03-31 | 2025-04-25 | 药康众拓(江苏)医药科技有限公司 | 氘代苯并噻吩类化合物及其药物组合物和用途 |
| PE20252775A1 (es) | 2023-04-05 | 2025-12-22 | Pfizer | Compuestos de pirido[4,3-d]pirimidina |
| EP4695262A1 (fr) | 2023-04-10 | 2026-02-18 | Pfizer Inc. | Composés pyrido[4,3-d] pyrimidine |
| CN116178256B (zh) * | 2023-04-19 | 2023-07-07 | 烟台大学 | 以sting为靶点的药用化合物及其制备方法和用途 |
| WO2025094035A1 (fr) | 2023-11-01 | 2025-05-08 | Pfizer Inc. | Agonistes du récepteur de type toll et conjugués associés |
| WO2026078593A1 (fr) | 2024-10-08 | 2026-04-16 | Sun Pharma Advanced Research Company Limited | Agonistes de sting et conjugués anticorps-médicament associés |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB532822A (en) | 1939-08-11 | 1941-01-31 | John David Kendall | Improvements in and relating to the production of ª‡-coumarilyl and ª‡-thionaphthenoyl-acetic acid esters |
| US4299769A (en) | 1980-04-28 | 1981-11-10 | American Cyanamid Company | ω-Heteroaroyl(propionyl or butyryl)-L-prolines |
| US4342690A (en) | 1980-04-28 | 1982-08-03 | American Cyanamid Company | ω-Heteroaroyl(propionyl or butyryl)-L-prolines |
| US4342691A (en) | 1980-04-28 | 1982-08-03 | American Cyanamid Company | ω-Heteroaroyl(propionyl or butyryl)-L-prolines |
| US4342689A (en) | 1980-04-28 | 1982-08-03 | American Cyanamid Company | ω-Heteroaroyl(propionyl or butyryl)-L-prolines |
| EP0146243A1 (fr) | 1983-10-31 | 1985-06-26 | Merck Frosst Canada Inc. | Inhibiteurs de la lipoxygénase |
| EP0350990B1 (fr) | 1988-07-11 | 1995-09-20 | Akzo Nobel N.V. | Dérivés de pyridazinone |
| ATE188379T1 (de) | 1992-10-14 | 2000-01-15 | Merck & Co Inc | Fibrinogenrezeptor-antagonisten |
| US5569655A (en) | 1993-09-14 | 1996-10-29 | Sterling Winthrop Inc. | Substituted heterocyclylisoquinolinium salts and compositions and method of use thereof |
| US6262055B1 (en) | 1998-06-03 | 2001-07-17 | Merck & Co., Inc. | HIV integrase inhibitors |
| JP2002517390A (ja) | 1998-06-03 | 2002-06-18 | メルク エンド カムパニー インコーポレーテッド | Ｈｉｖインテグラーゼ阻害薬 |
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| GB0018891D0 (en) | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
| WO2001070675A2 (fr) | 2000-03-24 | 2001-09-27 | Methylgene, Inc. | Inhibiteurs d'histone desacetylase |
| US6448288B1 (en) | 2000-05-17 | 2002-09-10 | University Of Massachusetts | Cannabinoid drugs |
| JP2004531238A (ja) | 2001-02-26 | 2004-10-14 | ファーマ パシフィック プロプライエタリー リミテッド | インターフェロン−アルファ誘導遺伝子 |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
| CN1845914A (zh) | 2003-09-02 | 2006-10-11 | 默克公司 | 用于治疗眼压过高的眼用组合物 |
| WO2005089777A1 (fr) | 2004-03-15 | 2005-09-29 | Karaolis David K R | Procede inhibant la proliferation et accroissant l'apoptose de cellules cancereuses |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| AU2006304897B2 (en) | 2005-10-18 | 2012-07-12 | Janssen Pharmaceutica N.V. | Method of inhibiting FLT3 kinase |
| EP1782826A1 (fr) | 2005-11-08 | 2007-05-09 | GBF Gesellschaft für Biotechnologische Forschung mbH | PQS, c-diGMP et leurs conjugués utilisés comme adjuvants et leur emploi dans des compositions pharmaceutiques |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| EP2262837A4 (fr) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | Protéines de liaison avec pd-1 |
| JP2012500855A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法 |
| US8552154B2 (en) | 2008-09-26 | 2013-10-08 | Emory University | Anti-PD-L1 antibodies and uses therefor |
| US8664255B2 (en) | 2008-10-20 | 2014-03-04 | The Texas A&M University System | Inhibitors of mycobacterium tuberculosis malate synthase, methods of making and uses thereof |
| EP3255060A1 (fr) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anticorps anti-pd-l1 et leur utilisation pour améliorer la fonction des lymphocytes t |
| WO2011066342A2 (fr) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Inhibition simultanée de pd-l1/pd-l2 |
| WO2012068702A1 (fr) | 2010-11-23 | 2012-05-31 | 中国医学科学院医药生物技术研究所 | Composés de benzo hétérocycliques insaturés à 5 éléments et procédés pour les préparer |
| JP5887947B2 (ja) | 2011-03-28 | 2016-03-16 | ソニー株式会社 | 透明導電膜、ヒータ、タッチパネル、太陽電池、有機ｅｌ装置、液晶装置および電子ペーパ |
| EP2697242B1 (fr) | 2011-04-13 | 2018-10-03 | Merck Sharp & Dohme Corp. | Dérivés de nucléosides à substitution 2'-azido et leurs procédés d'utilisation pour le traitement de maladies virales |
| MX368257B (es) | 2011-08-01 | 2019-09-26 | Genentech Inc | Antagonistas de unión al eje pd-1e inhibidores de mek y sus usos en el tratamiento de cáncer. |
| EP2858722B8 (fr) | 2012-06-08 | 2018-02-21 | Aduro BioTech, Inc. | Compositions et procédés pour immunothérapie anticancéreuse |
| CN103840995B (zh) | 2012-11-26 | 2017-10-24 | 华为技术有限公司 | Ip报文处理方法、装置及网络系统 |
| US9695212B2 (en) | 2012-12-13 | 2017-07-04 | Aduro Biotech, Inc. | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
| EP2934598B1 (fr) | 2012-12-19 | 2018-04-18 | Board Of Regents, The University Of Texas System | Ciblage pharmaceutique d'une voie de signalisation de dinucléotide cyclique chez un mammifère |
| EP2935304A1 (fr) | 2012-12-19 | 2015-10-28 | IDENIX Pharmaceuticals, Inc. | 4'-fluoro-nucléosides pour le traitement du vhc |
| WO2014139388A1 (fr) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques |
| WO2014179760A1 (fr) | 2013-05-03 | 2014-11-06 | The Regents Of The University Of California | Induction de dinucléotide cyclique de l'interféron de type i |
| US9549944B2 (en) | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
| PE20160080A1 (es) | 2013-05-18 | 2016-02-21 | Aduro Biotech Inc | Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon |
| WO2014189806A1 (fr) | 2013-05-18 | 2014-11-27 | Aduro Biotech, Inc. | Compositions et procédés d'inhibition de la signalisation dépendante du « stimulateur des gènes interférons » |
| US10176292B2 (en) | 2013-07-31 | 2019-01-08 | Memorial Sloan-Kettering Cancer Center | STING crystals and modulators |
| JP2016538344A (ja) * | 2013-11-19 | 2016-12-08 | ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | 癌処置としてのｓｔｉｎｇアゴニストの使用 |
| WO2015074145A1 (fr) | 2013-11-22 | 2015-05-28 | Brock University | Utilisation de dinucléotides cycliques fluorés comme adjuvants de vaccin oral |
| US9315523B2 (en) | 2013-12-06 | 2016-04-19 | Rutgers, The State University Of New Jersey | Cyclic dinucleosides |
| WO2015143712A1 (fr) | 2014-03-28 | 2015-10-01 | Merck Sharp & Dohme Corp. | Inhibiteurs nucléosidiques substitués en 4' de la transcriptase inverse |
| US10202411B2 (en) | 2014-04-16 | 2019-02-12 | Idenix Pharmaceuticals Llc | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV |
| CN103908468B (zh) | 2014-04-21 | 2017-02-08 | 上海捌加壹医药科技有限公司 | 环二核苷酸cGAMP在制备抗肿瘤药物中的应用 |
| CR20160564A (es) | 2014-06-04 | 2017-01-20 | Glaxosmithkline Ip Dev Ltd | Dinucleótidos cíclicos como moduladores de sting |
| US20170121315A1 (en) | 2014-06-12 | 2017-05-04 | Bayer Pharma Aktiengesellschaft | Heterobicyclically substituted 4-oxobutane acid derivatives and use thereof |
| US10695426B2 (en) | 2014-08-25 | 2020-06-30 | Pfizer Inc. | Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer |
| EP3546473B1 (fr) | 2014-12-16 | 2025-12-10 | Kayla Therapeutics | Dinucléotides cycliques [(2',5')p(3',5')p] fluorés pour l'induction de la cytokine |
| WO2016096577A1 (fr) | 2014-12-16 | 2016-06-23 | Invivogen | Utilisation combinée d'un agent chimiothérapeutique et d'un dinucléotide cyclique pour le traitement du cancer |
| US20180344758A1 (en) | 2014-12-17 | 2018-12-06 | Lipogen Llc | Method of Treating Cancer with cGAMP or cGAsMP |
| GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| EA035817B1 (ru) | 2015-03-10 | 2020-08-14 | Адуро Байотек, Инк. | Композиции и способы для активации сигналинга, зависимого от "гена стимулятора интерферона" |
| TW201717968A (zh) | 2015-07-14 | 2017-06-01 | 春季銀行製藥公司 | 誘導ｒｉｇ－ｉ和其他模式辨識受體之化合物及組成物 |
| CA3030582A1 (fr) | 2015-07-22 | 2017-01-26 | The Royal Institution For The Advancement Of Learning/Mcgill University | Composes et leurs utilisations dans le traitement de cancers et d'autres etats medicaux |
| EP3328418A1 (fr) | 2015-07-29 | 2018-06-06 | Novartis AG | Traitements combinés comprenant des molécules d'anticorps qui se lient à pd-1 |
| KR102222186B1 (ko) | 2015-08-13 | 2021-03-03 | 머크 샤프 앤드 돔 코포레이션 | Sting 효능제로서 시클릭 디-뉴클레오티드 화합물 |
| US9809597B2 (en) | 2015-08-20 | 2017-11-07 | The Board Of Trustees Of The Leland Stanford Junior University | Ganciclovir derivatives for modulating innate and adaptive immunity and for use in immunotherapy |
| JP2018534295A (ja) | 2015-10-28 | 2018-11-22 | アドゥロ バイオテック，インク． | 「インターフェロン遺伝子刺激因子」依存性シグナル伝達を活性化するための組成物および方法 |
| US20170146519A1 (en) * | 2015-11-20 | 2017-05-25 | Oregon Health & Science University | Sting agonists and methods of selecting sting agonists |
| CN107849084B (zh) | 2015-12-03 | 2021-09-14 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为sting调节剂的环状嘌呤二核苷酸 |
| DE212016000029U1 (de) | 2015-12-07 | 2017-07-30 | Opi Vi - Ip Holdco Llc | Zusammensetzungen von Antikörperkonstrukt-Agonist-Konjugaten |
| ES2986067T3 (es) | 2015-12-17 | 2024-11-08 | Novartis Ag | Moléculas de anticuerpos frente a PD-1 y usos de las mismas |
| KR102789862B1 (ko) | 2016-01-11 | 2025-04-03 | 인네이트 튜머 이뮤니티, 인코포레이티드 | Sting 활성과 연관된 상태 예컨대 암의 치료를 위한 시클릭 디뉴클레오티드 |
| US10723756B2 (en) | 2016-01-11 | 2020-07-28 | Innate Tumor Immunity Inc. | Cyclic dinucleotides for treating conditions associated with STING activity such as cancer |
| NZ746112A (en) | 2016-03-18 | 2023-01-27 | Immune Sensor Llc | Cyclic di-nucleotide compounds and methods of use |
| PT3440076T (pt) | 2016-04-07 | 2022-07-29 | Glaxosmithkline Ip Dev Ltd | Amidas heterocíclicas úteis como modeladores de proteína |
| JP2019510802A (ja) | 2016-04-07 | 2019-04-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | タンパク質調節物質として有用な複素環アミド |
| WO2017216726A1 (fr) | 2016-06-13 | 2017-12-21 | Glaxosmithkline Intellectual Property Development Limited | Pyridines substituées en tant qu'inhibiteurs de dnmt1 |
| EP3507367A4 (fr) | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | Composés dinucléotidiques cycliques d'acide nucléique bloqué et leurs utilisations |
| PT3523287T (pt) * | 2016-10-04 | 2021-10-06 | Merck Sharp & Dohme | Compostos de benzo[b]tiofeno como agonistas de sting |
-
2018
- 2018-07-30 JP JP2020505458A patent/JP2020530838A/ja active Pending
- 2018-07-30 WO PCT/US2018/044276 patent/WO2019027858A1/fr not_active Ceased
- 2018-07-30 EP EP18841645.7A patent/EP3661498A4/fr not_active Withdrawn
- 2018-07-30 MA MA049772A patent/MA49772A/fr unknown
- 2018-07-30 US US16/635,074 patent/US11285131B2/en active Active
- 2018-07-30 AU AU2018311966A patent/AU2018311966A1/en not_active Abandoned
- 2018-07-30 CA CA3071538A patent/CA3071538A1/fr active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3071538A1 (fr) | 2019-02-07 |
| EP3661498A4 (fr) | 2021-04-21 |
| RU2020109330A (ru) | 2021-09-06 |
| US20200330427A1 (en) | 2020-10-22 |
| WO2019027858A1 (fr) | 2019-02-07 |
| RU2020109330A3 (fr) | 2021-09-29 |
| JP2020530838A (ja) | 2020-10-29 |
| AU2018311966A1 (en) | 2020-02-13 |
| EP3661498A1 (fr) | 2020-06-10 |
| US11285131B2 (en) | 2022-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA49772A (fr) | Agonistes benzo[b]thiophène de sting pour le traitement du cancer | |
| MA47501A (fr) | Dérivé de di-nucléotides cycliques pour le traitement du cancer | |
| IL265678A (en) | Benzo[b]thiophene compounds as an agonist for interferon gene activator proteins (sting) | |
| MA49144A (fr) | Polythérapies pour le traitement du cancer | |
| MA47719A (fr) | Esketamine pour le traitement de la dépression | |
| EP3621592A4 (fr) | Polythérapies pour le traitement du cancer | |
| MA41449A (fr) | Polythérapies pour le traitement de cancers | |
| EP3488338A4 (fr) | Technologies pour le traitement adaptatif de tampons multiples | |
| MA50409A (fr) | Polythérapies pour le traitement du cancer | |
| EP3706753A4 (fr) | Inhibiteurs de la voie de l'adénosine pour le traitement du cancer | |
| EP3630196A4 (fr) | Polythérapies pour le traitement de cancers | |
| EP3351189A4 (fr) | Instrument de traitement pour endoscope | |
| EP3383407A4 (fr) | Conjugués de cytarabine pour le traitement du cancer | |
| EP3335041A4 (fr) | Biomarqueurs pour le traitement de la pelade | |
| EP3389645A4 (fr) | Combinaisons pour le traitement du cancer | |
| EP3383497A4 (fr) | Nouveaux anticorps pour le traitement de cancers | |
| MA45845A (fr) | Traitement d'association pour cancers hématologiques | |
| EP3359255A4 (fr) | Polythérapies pour le traitement du cancer | |
| EP3490561A4 (fr) | Combinaisons pour le traitement du cancer | |
| EP3316887A4 (fr) | Inhibiteurs de gls1 pour le traitement de maladies | |
| EP3318205A4 (fr) | Instrument de traitement pour endoscope | |
| EP3386967A4 (fr) | Combinaisons pour le traitement de calculs rénaux | |
| EP3349793A4 (fr) | Anti-s100a8 pour le traitement de la leucémie | |
| EP3503887A4 (fr) | Combinaisons pour le traitement du cancer | |
| MA44378A (fr) | Protéines de fusion immunogènes pour le traitement du cancer |